

From Referral to Randomization: Using AI to Close Clinical Trial Enrollment Gaps



Arturo Loaiza-Bonilla, MD, MSEd, FACP
Co Chief of Hematology and Medical Oncology
St. Luke's University Health Network

Katie Goodman, RN
Vice President Clinical Research American
Oncology Network Fort Myers, FL


Caroline Merillat
Director of Clinical Research – Cancer
Specialists of North Florida- Jacksonville, FL

Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Vice President for Clinical Research,
Woodruff Health Science Center

SPRING FORUM

1

How to Claim Your CE Credit



For CE credit, please visit:
<https://www.lecturepanda.com/r/2026NCODASpringForum>

- Credit requirements must be completed within 60 days of the program activity date.
- Upon completion, credit will be transmitted electronically to ACPE.
- All transmitted credit will be viewable in your CPE Monitor profile within 24 hours.
- CE codes will be displayed at the end of the presentation and will not be redistributed after this presentation.

SPRING FORUM

2

OBJECTIVES

1. Describe the basic principles of how AI-driven tools identify and match eligible patients for clinical trials in community oncology settings.
2. Recognize common barriers to clinical trial enrolment, including how AI-enabled processes can support improved clinical trial access and health equity across diverse patient populations
3. Identify key opportunities for AI to enhance interdisciplinary collaboration among oncology research coordinators, nurses, advanced practice providers, pharmacists, physicians, pharmacy technicians and administrative teams.
4. List examples of AI-integrated workflows used from referral through randomization and associated practice-level outcomes observed in real-world settings.

SPRING FORUM

3

DISCLOSURES 2026 NCI/NCODAS INTERNATIONAL SPRING FORUM

The following relevant financial relationships from the past 24 months have been identified and disclosed for the following faculty of this CE activity:

- **Arturo Loaiza-Bonilla, MD, MEd, FACP**
 - Guardant, AstraZeneca, Massvie Bio, HEARTio, Medscape, PSI CRO

No relevant financial relationships from the past 24 months have been identified for the following planners and faculty of this CE activity:

- **Caroline Merillat**
- **Katie Goodman, RN**
- **Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO**
- **Amanda McCauley, MSN, RN, OCN**
- **Tahsin Imam, PharmD**

2026 NCI/NCODAS INTERNATIONAL SPRING FORUM

4

Q1

Which of the following best describes how you currently utilize AI tools in your oncology practice?

- a. Assisting with patient pre-screening or identifying potential clinical trial matches
- b. Supporting documentation, note drafting, or communication workflows
- c. Using AI-enabled tools for patient education or teaching materials
- d. Leveraging predictive analytics or risk-stratification tools in care planning
- e. Not currently using AI in my role

2026 NCI/NCODAS INTERNATIONAL SPRING FORUM

5

Discussion Topic 1



How AI Can Transform Clinical Trials?


2026 NCI/NCODAS INTERNATIONAL SPRING FORUM

6

Q2


What is the primary obstacle in your workflow that makes clinical trial enrollment difficult?

- a. Difficulty identifying eligible patients in real time
- b. Communication gaps between clinic teams and research teams
- c. Patients declining due to logistical, financial, or social barriers
- d. Limited awareness of available trials among providers
- e. Complex eligibility criteria that are hard to interpret quickly
- f. Technology limitations or lack of integrated tools




7

Discussion Topic 2




**Using AI to Close the Gap:
Reducing Barriers to Clinical Trial Enrollment**




8

Discussion Topic 3



**Reimagining Interdisciplinary
Collaboration through the AI Evolution**



9

Q 3

What is the most significant concern you have about using AI in clinical trials?

- a. Accuracy or reliability of AI recommendations
- b. Data privacy or security risks
- c. Added workload or workflow disruption
- d. Lack of training or confidence in using AI
- e. Reduced human oversight or clinical judgment




10

Q 4


What would you most like to see AI achieve in the future within your clinical practice?

- a. Improve accuracy and speed of patient identification for clinical trials
- b. Reduce documentation burden and automate routine tasks
- c. Enhance communication and coordination across the care team
- d. Provide more personalized treatment insights and decision support
- e. Increase patient access, equity, and awareness related to clinical trials
- f. Offer better predictive tools for patient outcomes and care planning




11

Discussion Topic 4



**AI-Driven Healthcare:
Innovation, Real-World Application, and the
Next Era of Clinical Trials**



12

SUMMARY 2026 NCOA INTERNATIONAL SPRING FORUM





- AI-driven platforms analyze clinical, demographic, and real-time data to find and match patients to trials earlier, more accurately, and with fewer missed opportunities.
- AI supports overcoming patient, provider, and system-level barriers to clinical trial enrollment—helping expand access and improve representation across diverse populations.
- AI tools assist research coordinators, nurses, advanced practice providers, pharmacists, physicians, pharmacy technicians, and administrative teams by streamlining decision-making, automating routine tasks, and improving workflow clarity.
- AI is transforming clinical research by integrating advanced technology with responsible, evidence-driven practices—streamlining workflows, improving accuracy in trial matching, and expanding equitable access to care while strengthening safety and collaboration across the oncology landscape.

2026 NCOA INTERNATIONAL SPRING FORUM

13

QUESTION & ANSWER 2026 NCOA INTERNATIONAL SPRING FORUM

**From Referral to Randomization:
Using AI to Close Clinical Trial Enrollment Gaps**

 Arturo Loaiza-Bonilla, MD, MSEd, FACP	 Katie Goodman, RN
 Caroline Merillat	 Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO

2026 NCOA INTERNATIONAL SPRING FORUM

14

CE CODE 2026 NCOA INTERNATIONAL SPRING FORUM

**From Referral to Randomization:
Using AI to Close Clinical Trial
Enrollment Gaps**

2026 NCOA INTERNATIONAL SPRING FORUM

15



16
